---
figid: PMC4593065__nihms714401f1
figlink: /pmc/articles/PMC4593065/figure/F1/
number: Figure 1
caption: 'Schematic representation of the IGF-1R signaling network and nodes of therapeutic
  blockade. The IGF-1R signaling pathway is composed of three receptor tyrosine kinases
  - insulin-like growth factor-1 receptor (IGF-1R), insulin-like growth factor-2 receptor
  (IGF-2R), and insulin receptor (INSR); three ligands – Insulin, IGF-1, and IGF-2
  (formerly known as somatomedins) (, ); and six serum Insulin-like Growth Factor
  Binding Proteins (IGFBPs). The IGFBPs, of which IGFBP3 is the most common, serve
  as regulators of the pathway by determining the bioavailability of IGF-1 and IGF-2
  ligands (). Both IGF-1 and IGF-2 exert their effects through autocrine, paracrine,
  and endocrine mechanisms, and both can activate the IGF-1R pathway. For simplification,
  IGF-1 ligand only is shown binding to IGF-1R. IGF-1 binding to IGF-1R promotes receptor
  homodimerization or heterodimerization with INSR. Ligand-activated IGF-1R first
  binds to intracellular adaptor proteins, such as insulin receptor substrate1 (IRS1)
  and SHC. These adaptor proteins transmit signals through the phosphatidyl-inositol-3
  kinase (PI3K)-AKT1-mammalian target of rapamycin (MTOR) pathway and through the
  mitogen activated protein kinase (MAPK) pathway. Activated IGF-1R promotes cellular
  motility through activation of IRS2, which alters integrin expression through poorly
  understood mechanisms involving the small G protein RHOA, focal adhesion kinase
  (FAK), Rho-kinase (ROCK), PI3K, and other signaling molecules. Of note, IGF2R is
  a repository for IGF-2, and it has no intracellular signaling activity. IGF-2R acts
  as a tumor suppressor gene, as when IGF-2R function is lost, IGF-2 is able to bind
  IGF-1R and promote tumorigenesis (). Targets for potential monotherapy and combinatorial
  therapeutic strategies are noted in the figure. TKI: tyrosine kinase inhibitor.
  mAb: monoclonal antibody.'
pmcid: PMC4593065
papertitle: 'Molecular Pathways: Clinical Applications and Future Direction of Insulin-Like
  Growth Factor-1 Receptor Pathway Blockade.'
reftext: Wade T. Iams, et al. Clin Cancer Res. ;21(19):4270-4277.
pmc_ranked_result_index: '101344'
pathway_score: 0.9778383
filename: nihms714401f1.jpg
figtitle: The IGF-1R signaling network and nodes of therapeutic blockade
year: ''
organisms: Homo sapiens
ndex: 640adc86-debd-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4593065__nihms714401f1.html
  '@type': Dataset
  description: 'Schematic representation of the IGF-1R signaling network and nodes
    of therapeutic blockade. The IGF-1R signaling pathway is composed of three receptor
    tyrosine kinases - insulin-like growth factor-1 receptor (IGF-1R), insulin-like
    growth factor-2 receptor (IGF-2R), and insulin receptor (INSR); three ligands
    – Insulin, IGF-1, and IGF-2 (formerly known as somatomedins) (, ); and six serum
    Insulin-like Growth Factor Binding Proteins (IGFBPs). The IGFBPs, of which IGFBP3
    is the most common, serve as regulators of the pathway by determining the bioavailability
    of IGF-1 and IGF-2 ligands (). Both IGF-1 and IGF-2 exert their effects through
    autocrine, paracrine, and endocrine mechanisms, and both can activate the IGF-1R
    pathway. For simplification, IGF-1 ligand only is shown binding to IGF-1R. IGF-1
    binding to IGF-1R promotes receptor homodimerization or heterodimerization with
    INSR. Ligand-activated IGF-1R first binds to intracellular adaptor proteins, such
    as insulin receptor substrate1 (IRS1) and SHC. These adaptor proteins transmit
    signals through the phosphatidyl-inositol-3 kinase (PI3K)-AKT1-mammalian target
    of rapamycin (MTOR) pathway and through the mitogen activated protein kinase (MAPK)
    pathway. Activated IGF-1R promotes cellular motility through activation of IRS2,
    which alters integrin expression through poorly understood mechanisms involving
    the small G protein RHOA, focal adhesion kinase (FAK), Rho-kinase (ROCK), PI3K,
    and other signaling molecules. Of note, IGF2R is a repository for IGF-2, and it
    has no intracellular signaling activity. IGF-2R acts as a tumor suppressor gene,
    as when IGF-2R function is lost, IGF-2 is able to bind IGF-1R and promote tumorigenesis
    (). Targets for potential monotherapy and combinatorial therapeutic strategies
    are noted in the figure. TKI: tyrosine kinase inhibitor. mAb: monoclonal antibody.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IGF1R
  - IGF1
  - IGFBP7
  - IRS1
  - IRS2
  - IGFBP5
  - SHC1
  - SOS1
  - INSR
  - IGF2
  - ARAF
  - RAF1
  - IGFBP1
  - IGF2R
  - IGFBP6
  - AKT1
  - BAD
  - MAPK1
  - MAPK3
  - PTK2
  - GRB2
  - MTOR
  - SART3
  - IGFBP3
  - IGFBP4
  - BRAF
  - IGFBP2
  - SHC4
  - MAP2K2
  - ROCK2
  - SHC2
  - SOS2
  - NRAS
  - MAP2K1
  - KRAS
  - RHOA
  - ROCK1
  - HRAS
  - SHC3
  - Temsirolimus
  - Ridaforolimus
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
genes:
- word: IGF-1R
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: IGF-1/IGF-2
  symbol: IGF1
  source: hgnc_symbol
  hgnc_symbol: IGF1
  entrez: '3479'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP7
  entrez: '3490'
- word: IRS1
  symbol: IRS1
  source: hgnc_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: IRS2
  symbol: IRS2
  source: hgnc_symbol
  hgnc_symbol: IRS2
  entrez: '8660'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP5
  entrez: '3488'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC1
  entrez: '6464'
- word: SOS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: IGF-1R/INSR
  symbol: INSR
  source: hgnc_symbol
  hgnc_symbol: INSR
  entrez: '3643'
- word: IGF-1/IGF-2
  symbol: IGF-II
  source: hgnc_alias_symbol
  hgnc_symbol: IGF2
  entrez: '3481'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP1
  entrez: '3484'
- word: IGF-2R
  symbol: IGF2R
  source: hgnc_symbol
  hgnc_symbol: IGF2R
  entrez: '3482'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP6
  entrez: '3489'
- word: AKT1
  symbol: AKT1
  source: hgnc_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: BAD
  symbol: BAD
  source: hgnc_symbol
  hgnc_symbol: BAD
  entrez: '572'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: FAK
  symbol: FAK
  source: hgnc_alias_symbol
  hgnc_symbol: PTK2
  entrez: '5747'
- word: GRB2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: p110
  symbol: p110
  source: hgnc_alias_symbol
  hgnc_symbol: SART3
  entrez: '9733'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP3
  entrez: '3486'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP4
  entrez: '3487'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP2
  entrez: '3485'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC4
  entrez: '399694'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ROCK
  symbol: ROCK
  source: bioentities_symbol
  hgnc_symbol: ROCK2
  entrez: '9475'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC2
  entrez: '25759'
- word: SOS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RHOA
  symbol: RHOA
  source: hgnc_symbol
  hgnc_symbol: RHOA
  entrez: '387'
- word: ROCK
  symbol: ROCK
  source: bioentities_symbol
  hgnc_symbol: ROCK1
  entrez: '6093'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC3
  entrez: '53358'
chemicals:
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Ridaforolimus
  source: MESH
  identifier: C515074
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
